SEC Filing Summary: AmerisourceBergen Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on January 17, 2003. The report details the closing of a strategic acquisition under Item 5 (Other Events).
Key Financial Metrics and Transaction Details
The filing reports the acquisition of US Bioservices Corporation, a provider of high-cost, complex therapy management and reimbursement support. Key financial terms include:
- Base Purchase Price: Approximately $160 million (including assumed debt).
- Contingency Payments: Up to a maximum of $28 million.
- Equity Consideration: Issuance of 2,399,091 shares of common stock.
The filing does not provide specific revenue, profit, cash flow, margin, or liquidity metrics for the Company or the acquired entity within this document.
Material Changes
The primary material change is the expansion of the Company's service portfolio through the acquisition of US Bioservices Corporation. This transaction adds capabilities in managing complex therapies and reimbursement support.
Outlook, Risks, and Unusual Items
Management commentary is limited to the announcement of the transaction closing. The filing notes the potential for future cash outflows related to the $28 million maximum in contingency payments. No specific risks or contingencies beyond the standard terms of the acquisition are detailed in this report.
Investor Verification Checklist
- Verify the final valuation of US Bioservices Corporation including any realized contingency payments.
- Review the impact of the 2,399,091 new shares on existing shareholder dilution.
- Examine subsequent financial reports to assess the integration and revenue contribution of US Bioservices.
- Confirm the specific amount of debt assumed in the $160 million purchase price.